These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 35486097)
1. Molecular Pathways and Mechanisms of BRAF in Cancer Therapy. Poulikakos PI; Sullivan RJ; Yaeger R Clin Cancer Res; 2022 Nov; 28(21):4618-4628. PubMed ID: 35486097 [TBL] [Abstract][Full Text] [Related]
2. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644 [TBL] [Abstract][Full Text] [Related]
3. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830 [TBL] [Abstract][Full Text] [Related]
4. Clinical Development of BRAF plus MEK Inhibitor Combinations. Subbiah V; Baik C; Kirkwood JM Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454 [TBL] [Abstract][Full Text] [Related]
5. Targeting Baik CS; Myall NJ; Wakelee HA Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464 [TBL] [Abstract][Full Text] [Related]
6. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212 [TBL] [Abstract][Full Text] [Related]
7. Adverse Event Management in Patients with Chalmers A; Cannon L; Akerley W Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499 [TBL] [Abstract][Full Text] [Related]
8. A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker. Turshudzhyan A; Vredenburgh J Curr Oncol; 2020 Dec; 28(1):196-202. PubMed ID: 33704186 [TBL] [Abstract][Full Text] [Related]
9. Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors. Adashek JJ; Menta AK; Reddy NK; Desai AP; Roszik J; Subbiah V Mol Cancer Ther; 2022 Jun; 21(6):871-878. PubMed ID: 35413124 [TBL] [Abstract][Full Text] [Related]
10. MEK inhibitors for the treatment of non-small cell lung cancer. Han J; Liu Y; Yang S; Wu X; Li H; Wang Q J Hematol Oncol; 2021 Jan; 14(1):1. PubMed ID: 33402199 [TBL] [Abstract][Full Text] [Related]
11. Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy. Gouda MA; Subbiah V ESMO Open; 2023 Apr; 8(2):100788. PubMed ID: 36842301 [TBL] [Abstract][Full Text] [Related]
12. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Roskoski R Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722 [TBL] [Abstract][Full Text] [Related]
14. Encorafenib plus binimetinib in patients with Riely GJ; Ahn MJ; Felip E; Ramalingam SS; Smit EF; Tsao AS; Alcasid A; Usari T; Wissel PS; Wilner KD; Johnson BE Future Oncol; 2022 Mar; 18(7):781-791. PubMed ID: 34918546 [TBL] [Abstract][Full Text] [Related]
15. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF Hong SP; Ahn SK Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859 [TBL] [Abstract][Full Text] [Related]
16. BRAF as a target for cancer therapy. Dienstmann R; Tabernero J Anticancer Agents Med Chem; 2011 Mar; 11(3):285-95. PubMed ID: 21426297 [TBL] [Abstract][Full Text] [Related]
17. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience. Khunger A; Khunger M; Velcheti V Ther Adv Respir Dis; 2018; 12():1753466618767611. PubMed ID: 29595366 [TBL] [Abstract][Full Text] [Related]
18. Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions. Riudavets M; Cascetta P; Planchard D Lung Cancer; 2022 Jul; 169():102-114. PubMed ID: 35696864 [TBL] [Abstract][Full Text] [Related]
19. Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with Ortiz-Cuaran S; Mezquita L; Swalduz A; Aldea M; Mazieres J; Leonce C; Jovelet C; Pradines A; Avrillon V; Chumbi Flores WR; Lacroix L; Loriot Y; Westeel V; Ngo-Camus M; Tissot C; Raynaud C; Gervais R; Brain E; Monnet I; Giroux Leprieur E; Caramella C; Mahier-Aït Oukhatar C; Hoog-Labouret N; de Kievit F; Howarth K; Morris C; Green E; Friboulet L; Chabaud S; Guichou JF; Perol M; Besse B; Blay JY; Saintigny P; Planchard D Clin Cancer Res; 2020 Dec; 26(23):6242-6253. PubMed ID: 32859654 [TBL] [Abstract][Full Text] [Related]
20. Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. Negrao MV; Raymond VM; Lanman RB; Robichaux JP; He J; Nilsson MB; Ng PKS; Amador BE; Roarty EB; Nagy RJ; Banks KC; Zhu VW; Ng C; Chae YK; Clarke JM; Crawford JA; Meric-Bernstam F; Ignatius Ou SH; Gandara DR; Heymach JV; Bivona TG; McCoach CE J Thorac Oncol; 2020 Oct; 15(10):1611-1623. PubMed ID: 32540409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]